You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Plaque psoriasis,TREMFYA is indicated for the treatment of adult patients (18 years or older) with moderate to
severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,TREMFYA is indicated for the treatment of adult patients with active psoriatic arthritis, who
have had an inadequate response to, or are intolerant to prior DMARD therapy.,Ulcerative colitis,TREMFYA is indicated for the treatment of adult patients with moderately to severely active
ulcerative colitis who have had an inadequate response, lost response, or were intolerant to
either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.,Crohns disease,TREMFYA is indicated for the treatment of adult patients with moderately to severely active
Crohns disease who have had an inadequate response, lost response, or were intolerant to
either conventional therapy or a biologic treatment.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Plaque psoriasis,TREMFYA is indicated for the treatment of adult patients (18 years or older) with moderate to
severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,TREMFYA is indicated for the treatment of adult patients with active psoriatic arthritis, who
have had an inadequate response to, or are intolerant to prior DMARD therapy.,Ulcerative colitis,TREMFYA is indicated for the treatment of adult patients with moderately to severely active
ulcerative colitis who have had an inadequate response, lost response, or were intolerant to
either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.,Crohns disease,TREMFYA is indicated for the treatment of adult patients with moderately to severely active
Crohns disease who have had an inadequate response, lost response, or were intolerant to
either conventional therapy or a biologic treatment.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Plaque psoriasis,TREMFYA is indicated for the treatment of adult patients (18 years or older) with moderate to
severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,TREMFYA is indicated for the treatment of adult patients with active psoriatic arthritis, who
have had an inadequate response to, or are intolerant to prior DMARD therapy.,Ulcerative colitis,TREMFYA is indicated for the treatment of adult patients with moderately to severely active
ulcerative colitis who have had an inadequate response, lost response, or were intolerant to
either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.,Crohns disease,TREMFYA is indicated for the treatment of adult patients with moderately to severely active
Crohns disease who have had an inadequate response, lost response, or were intolerant to
either conventional therapy or a biologic treatment.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Plaque psoriasis,TREMFYA is indicated for the treatment of adult patients (18 years or older) with moderate to
severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,TREMFYA is indicated for the treatment of adult patients with active psoriatic arthritis, who
have had an inadequate response to, or are intolerant to prior DMARD therapy.,Ulcerative colitis,TREMFYA is indicated for the treatment of adult patients with moderately to severely active
ulcerative colitis who have had an inadequate response, lost response, or were intolerant to
either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.,Crohns disease,TREMFYA is indicated for the treatment of adult patients with moderately to severely active
Crohns disease who have had an inadequate response, lost response, or were intolerant to
either conventional therapy or a biologic treatment.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Plaque psoriasis,TREMFYA is indicated for the treatment of adult patients (18 years or older) with moderate to
severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis,TREMFYA is indicated for the treatment of adult patients with active psoriatic arthritis, who
have had an inadequate response to, or are intolerant to prior DMARD therapy.,Ulcerative colitis,TREMFYA is indicated for the treatment of adult patients with moderately to severely active
ulcerative colitis who have had an inadequate response, lost response, or were intolerant to
either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.,Crohns disease,TREMFYA is indicated for the treatment of adult patients with moderately to severely active
Crohns disease who have had an inadequate response, lost response, or were intolerant to
either conventional therapy or a biologic treatment.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
